pp32 Reduction Induces Differentiation of TSU-Pr1 Cells

American Journal of Pathology

Volumn 164, Issue 1, 2004, Pages 273-283

  Brody, Jonathan R ^a   Kadkol, Shrihari S ^a   Hauer, M Claire ^a   Rajaii, Fatemeh ^a   Lee, Jessica ^a   Pasternack, Gary R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H4; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN PP32; UNCLASSIFIED DRUG; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLINE; HISTONE; INTERLEUKIN 6; NONHISTONE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHOPROTEIN 32; PROTEIN; SET PROTEIN, HUMAN; TEMPLATE ACTIVATING FACTOR I; TEMPLATE ACTIVATING FACTOR-I; TRANSCRIPTION FACTOR;

ACETYLATION; ADENOCARCINOMA; ARTICLE; BASAL CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL GROWTH; CELL POPULATION; COMPLEX FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL; BIOSYNTHESIS; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; IMAGE PROCESSING; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ACETYLATION; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; GENE EXPRESSION REGULATION; HISTONES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERLEUKIN-6; MALE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOPROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; PROTEINS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 1542469606     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63117-3     Document Type: Article

References (30)

1. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK: Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202
2. Kadkol SS, Brody JR, Epstein JI, Kuhajda FP, Pasternack GR: Novel nuclear phosphoprotein pp32 is highly expressed in intermediate-and high-grade prostate cancer. Prostate 1998, 34:231-237
3. Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR: Identification of sequences required for inhibition of oncogene-mediated transformation by pp32. J Biol Chem 1999, 274:20053-20055
4. Bai J, Brody JR, Kadkol SS, Pasternack GR: Tumor suppression and potentiation by manipulation of pp32 expression. Oncogene 2001, 20:2153-2160
5. De Marzo AM, Nelson WG, Meeker AK, Coffey DS: Stem cell features of benign and malignant prostate epithelial cells. J Urol 1998, 160: 2381-2392
6. Walensky LD, Coffey DS, Chen TH, Wu TC, Pasternack GR: A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res 1993, 53:4720-4726
7. Mencinger M, Panagopoulos I, Contreras JA, Mitelman F, Aman P: Expression analysis and chromosomal mapping of a novel human gene, APRIL, encoding an acidic protein rich in leucines. Biochim Biophys Acta 1998, 1395:176-180
8. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ: Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol 1998, 9:1873-1880
9. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M: The oncoprotein Set/TAF-1 beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 2002, 277:25026-25031
10. Brennan CM, Gallouzi IE, Steitz JA: Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol 2000, 151:1-14
11. Harada JN, Shevchenko A, Pallas DC, Berk AJ: Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 2002, 76:9194-9206
12. Carter BS, Epstein JI, Isaacs WB: Ras gene mutations in human prostate cancer. Cancer Res 1990, 50:6830-6832
13. van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ: TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 2001, 61:6340-6344
14. Takahashi N, Shimizu T, Takeda K: Low-dose staurosporine suppresses proliferation and induces neurites in human prostatic cancer TSU-Pr1 cells. Prostate 2000, 44:328-333
15. Sugibayashi R, Shimizu T, Suzuki T, Yamamoto N, Hamada H, Takeda K: Upregulation of p21(WAF1/CIP1) leads to morphologic changes and esterase activity in TPA-mediated differentiation of human prostate cancer cell line TSU-Pr1. Oncogene 2001, 20:1220-1228
16. Bonkhoff H: Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 2001, 12(Suppl 2):S141-S144
17. Cox ME, Deeble PD, Lakhani S, Parsons SJ: Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999, 59:3821-3830
18. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Slezak JM, Cheng L: Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 2002, 168:1204-1211
19. Carroll PR, Waldman FM, Rosenau W, Cohen MB, Vapnek JM, Fong P, Narayan P, Mayall BH: Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. J Urol 1993, 149:403-407
20. Seo SB, Macfarlan T, McNamara P, Hong R, Mukai Y, Heo S, Chakravarti D: Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex. J Biol Chem 2002, 277:14005-14010
21. Li M, Makkinje A, Damuni Z: Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry 1996, 35:6998-7002
22. Li X, Yost HJ, Virshup DM, Seeling JM: Protein phosphatase 2A and its B56 regulatory subunit inhibit Wnt signaling in Xenopus. EMBO J 2001, 20:4122-4131
23. Seeling JM, Miller JR, Gil R, Moon RT, White R, Virshup DM: Regulation of beta-catenin signaling by the B56 subunit of protein phosphatase 2A. Science 1999, 283:2089-2091
24. Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D: Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001, 104:119-130
25. Deeble PD, Murphy DJ, Parsons SJ, Cox ME: Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001, 21:8471-8482
26. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000, 60: 5165-5170
27. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001, 61:8492-8497
28. Nabors LB, Gillespie GY, Harkins L, King PH: HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine-and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001, 61:2154-2161
29. Mori S, Murakami-Mori K, Bonavida B: Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Biophys Res Commun 1999, 257:609-614
30. He LZ, Tolentino T, Grayson P, Zhong S, Warrell Jr RP, Rifkind RA, Marks PA, Richon VM, Pandolfi PP: Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest 2001, 108:1321-1330